Literature DB >> 23506280

Continuous veno-venous hemofiltration for massive rhabdomyolysis after malignant hyperthermia: report of 2 cases.

Shudong Fang1, Hui Xu, Yesen Zhu, Hong Jiang.   

Abstract

We present 2 cases of fulminant malignant hyperthermia (MH), complicated with massive rhabdomyolysis. The patients were successfully treated in the intensive care unit of our university teaching hospital, despite the lack of availability of dantrolene in our country, by early application of continuous veno-venous hemofiltration (CVVH). Both male patients developed fulminant malignant hyperthermia during anesthesia for oromaxillofacial surgery. CVVH was employed when the values of creatine phosphokinase (CPK), myoglobin (Mb), and lactate dehydrogenase (LDH) increased significantly. After emergency treatment and CVVH therapy, the values of CPK, Mb, and LDH in the blood plasma of the patients decreased significantly. The complications, including acute renal failure, disseminated intravascular coagulation, and acute respiratory distress syndrome were also treated without any obvious organ damage. Early detection and management are the keys to treat MH successfully. CVVH is a valuable therapeutic application in the initial/critical management of severe rhabdomyolysis. If these complications occur even with initial treatment with dantrolene, our experiences may be useful adjunctive treatments to consider.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23506280      PMCID: PMC3601726          DOI: 10.2344/11-000240.1

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  11 in total

1.  Malignant hyperthermia as a cause for postoperative rhabdomyolysis.

Authors:  F Wappler; M Fiege
Journal:  Anesthesiology       Date:  2000-04       Impact factor: 7.892

Review 2.  Malignant hyperthermia: advances in clinical management and diagnosis.

Authors:  P M Hopkins
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

3.  Continuous veno-venous hemofiltration for the immediate management of massive rhabdomyolysis after fulminant malignant hyperthermia in a bodybuilder.

Authors:  M R Schenk; D H Beck; M Nolte; W J Kox
Journal:  Anesthesiology       Date:  2001-06       Impact factor: 7.892

4.  Delayed postoperative rhabdomyolysis in a patient subsequently diagnosed as malignant hyperthermia susceptible.

Authors:  Kevin A McKenney; Stephen J Holman
Journal:  Anesthesiology       Date:  2002-03       Impact factor: 7.892

Review 5.  Rhabdomyolysis and myohemoglobinuric acute renal failure.

Authors:  R A Zager
Journal:  Kidney Int       Date:  1996-02       Impact factor: 10.612

6.  Myoglobin clearance and removal during continuous venovenous hemofiltration.

Authors:  S L Amyot; M Leblanc; Y Thibeault; D Geadah; J Cardinal
Journal:  Intensive Care Med       Date:  1999-10       Impact factor: 17.440

7.  Malignant hyperthermia in China.

Authors:  Zhong-huang Xu; Ai-lun Luo; Xiang-yang Guo; Hong-zhi Ren; Ying-lin Wang; Xue Zhang; Yu-guang Huang; Tie-hu Ye
Journal:  Anesth Analg       Date:  2006-10       Impact factor: 5.108

8.  A clinical grading scale to predict malignant hyperthermia susceptibility.

Authors:  M G Larach; A R Localio; G C Allen; M A Denborough; F R Ellis; G A Gronert; R F Kaplan; S M Muldoon; T E Nelson; H Ording
Journal:  Anesthesiology       Date:  1994-04       Impact factor: 7.892

9.  Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis.

Authors:  D Nicolau; Y S Feng; A H Wu; S P Bernstein; C H Nightingale
Journal:  Int J Artif Organs       Date:  1998-04       Impact factor: 1.595

Review 10.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.